Literature DB >> 10097064

Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.

E J Martinez1, T Owa, S L Schreiber, E J Corey.   

Abstract

A series of totally synthetic molecules that are structurally related to the marine natural product ecteinascidin 743 (Et 743) has been prepared and evaluated as antitumor agents. The most active of these, phthalascidin, is very similar to Et 743 with regard to in vitro potency and mode of action across a variety of cell types. The antiproliferative activity of phthalascidin (IC50 = 0.1-1 nM) is greater than that of the agents Taxol, camptothecin, adriamycin, mitomycin C, cisplatin, bleomycin, and etoposide by 1-3 orders of magnitude, and the mechanism of action is clearly different from these currently used drugs. Phthalascidin and Et 743 induce DNA-protein cross-linking and, although they seem to interact with topoisomerase (topo) I (but not topo II), topo I may not be the primary protein target of these agents. Phthalascidin and Et 743 show undiminished potency in camptothecin- and etoposide-resistant cells. Phthalascidin is more readily synthesized and more stable than Et 743, which is currently undergoing clinical trials. The relationship of chemical structure and antitumor activity for this class of molecules has been clarified by this study.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10097064      PMCID: PMC22321          DOI: 10.1073/pnas.96.7.3496

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  11 in total

1.  DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata.

Authors:  Y Pommier; G Kohlhagen; C Bailly; M Waring; A Mazumder; K W Kohn
Journal:  Biochemistry       Date:  1996-10-15       Impact factor: 3.162

2.  Mapping DNA-protein interactions by cross-linking.

Authors:  A D Mirzabekov; S G Bavykin; A V Belyavsky; V L Karpov; O V Preobrazhenskaya; V V Shick; K K Ebralidse
Journal:  Methods Enzymol       Date:  1989       Impact factor: 1.600

3.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

Authors:  P M O'Connor; J Jackman; I Bae; T G Myers; S Fan; M Mutoh; D A Scudiero; A Monks; E A Sausville; J N Weinstein; S Friend; A J Fornace; K W Kohn
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

4.  Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities in vivo.

Authors:  R Sakai; K L Rinehart; Y Guan; A H Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

5.  Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture.

Authors:  A H Cory; T C Owen; J A Barltrop; J G Cory
Journal:  Cancer Commun       Date:  1991-07

6.  DNase I hypersensitivity is independent of endogenous topoisomerase II activity during chicken erythrocyte differentiation.

Authors:  M T Muller; V B Mehta
Journal:  Mol Cell Biol       Date:  1988-09       Impact factor: 4.272

7.  Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D.

Authors:  D K Trask; M T Muller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

8.  Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA.

Authors:  M T Muller; W P Pfund; V B Mehta; D K Trask
Journal:  EMBO J       Date:  1985-05       Impact factor: 11.598

9.  Rapid detection and isolation of covalent DNA/protein complexes: application to topoisomerase I and II.

Authors:  D K Trask; J A DiDonato; M T Muller
Journal:  EMBO J       Date:  1984-03       Impact factor: 11.598

10.  Stereo (C7)-dependent topoisomerase II inhibition and tumor growth suppression by a new quinolone, BO-2367.

Authors:  T Yoshinari; E Mano; H Arakawa; M Kurama; T Iguchi; S Nakagawa; N Tanaka; A Okura
Journal:  Jpn J Cancer Res       Date:  1993-07
View more
  19 in total

1.  Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.

Authors:  Y Takebayashi; P Pourquier; A Yoshida; G Kohlhagen; Y Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

2.  Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

Authors:  M Minuzzo; S Marchini; M Broggini; G Faircloth; M D'Incalci; R Mantovani
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 3.  Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.

Authors:  Zhiyan Xiao; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-09-11       Impact factor: 12.944

4.  Concise total syntheses of (-)-jorunnamycin A and (-)-jorumycin enabled by asymmetric catalysis.

Authors:  Eric R Welin; Aurapat Ngamnithiporn; Max Klatte; Guillaume Lapointe; Gerit M Pototschnig; Martina S J McDermott; Dylan Conklin; Christopher D Gilmore; Pamela M Tadross; Christopher K Haley; Kenji Negoro; Emil Glibstrup; Christian U Grünanger; Kevin M Allan; Scott C Virgil; Dennis J Slamon; Brian M Stoltz
Journal:  Science       Date:  2018-12-20       Impact factor: 47.728

5.  Regioselectivity of Pictet-Spengler Cyclization Reactions to Construct the Pentacyclic Frameworks of the Ecteinascidin-Saframycin Class of Tetrahydroisoquinoline Antitumor Antibiotics.

Authors:  Guillaume Vincent; Jonathan W Lane; Robert M Williams
Journal:  Tetrahedron Lett       Date:  2007-05-21       Impact factor: 2.415

6.  Synthesis and characterization of a small analogue of the anticancer natural product leinamycin.

Authors:  Kripa Keerthi; Anuruddha Rajapakse; Daekyu Sun; Kent S Gates
Journal:  Bioorg Med Chem       Date:  2012-10-27       Impact factor: 3.641

Review 7.  Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.

Authors:  V H Le; M Inai; R M Williams; T Kan
Journal:  Nat Prod Rep       Date:  2015-02       Impact factor: 13.423

8.  Identification of GAPDH as a protein target of the saframycin antiproliferative agents.

Authors:  Chengguo Xing; Jacob R LaPorte; Joseph K Barbay; Andrew G Myers
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

9.  Dynamics and evolution of β-catenin-dependent Wnt signaling revealed through massively parallel clonogenic screening.

Authors:  Pavak K Shah; Matthew P Walker; Christopher E Sims; Michael B Major; Nancy L Allbritton
Journal:  Integr Biol (Camb)       Date:  2014-05-28       Impact factor: 2.192

10.  Microarray-based transcriptional profiling of renieramycin M and jorunnamycin C, isolated from Thai marine organisms.

Authors:  Kornvika Charupant; Khanit Suwanborirux; Naomi Daikuhara; Masashi Yokoya; Rie Ushijima-Sugano; Takatoshi Kawai; Takashi Owa; Naoki Saito
Journal:  Mar Drugs       Date:  2009-10-19       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.